Журнал «Травма» Том 27, №2, 2026
Вернуться к номеру
Рекомендації щодо діагностики, профілактики та лікування остеопорозу у чоловіків
Авторы: Григор’єва Н.В. (1), Корж М.О. (2, 3), Тронько М.Д. (4, 5), Маньковський Б.М. (1, 5), Яцишин Р.І. (6),
Головач І.Ю. (7), Страфун С.С. (8), Сміян С.І. (9), Гурженко Ю.М. (10), Рекалов Д.Г. (11), Нікітін О.Д. (12), Орленко В.Л. (4), Проценко Г.О. (11), Калашніков А.В. (8), Лучицький В.Є. (4), Мусієнко А.С. (1), за підтримки Української асоціації остеопорозу
(1) - Державна установа «Інститут геронтології імені Д.Ф. Чеботарьова Національної академії медичних наук України», м. Київ, Україна
(2) - Державна установа «Інститут патології хребта та суглобів імені проф. М.І. Ситенка Національної академії медичних наук України», м. Харків, Україна
(3) - Харківський національний медичний університет, м. Харків, Україна
(4) - Державна установа «Інститут ендокринології та обміну речовин імені В.П. Комісаренка Національної академії медичних наук України», м. Київ, Україна
(5) - Національний університет охорони здоров’я України імені П.Л. Шупика, м. Київ, Україна
(6) - Івано-Франківський національний медичний університет, м. Івано-Франківськ, Україна
(7) - Клінічна лікарня «Феофанія» Державного управління справами, м. Київ, Україна
(8) - Державна установа «Національний інститут травматології та ортопедії Національної академії медичних наук України», м. Київ, Україна
(9) - Тернопільський національний медичний університет імені І.Я. Горбачевського, м. Тернопіль, Україна
(10) - Державна установа «Інститут урології імені акад. О.Ф. Возіанова Національної академії медичних наук України», м. Київ, Україна
(11) - Державна установа «Національний науковий центр «Інститут кардіології, клінічної та регенеративної медицини імені академіка М.Д. Стражеска» Національної академії медичних наук України», м. Київ, Україна
(12) - Національний медичний університет імені О.О. Богомольця, м. Київ, Україна
Рубрики: Травматология и ортопедия
Разделы: Справочник специалиста
Версия для печати
Резюме
Дані сучасних літературних джерел свідчать про недостатню оцінку, діагностику та лікування остеопорозу у чоловіків, що має негативні медико-соціальні наслідки для суспільства. Метою даної роботи було створення перших в Україні рекомендацій щодо діагностики, профілактики та лікування остеопорозу у чоловіків для поліпшення обізнаності медичної спільноти та підвищення ефективності надання медичної допомоги. Для реалізації мети була створена мультидисциплінарна експертна група, яка на основі всеосяжного аналізу сучасних літературних джерел та їх оцінки за допомогою системи GRADE сформулювала 19 рекомендацій, що стосуються факторів ризику, скринінгу, діагностики, немедикаментозного та фармакологічного лікування остеопорозу у чоловіків, та успішно проголосувала за них. Автори запропонували алгоритм менеджменту остеопорозу у чоловіків залежно від віку та ризику остеопоротичних переломів. Положення підтримані Українською асоціацією остеопорозу і рекомендовані до застосування на різних ланках надання медичної допомоги спеціалістами різного фаху.
Data from modern literature sources indicate insufficient assessment, diagnosis and treatment of osteoporosis in men, which has negative medical and social consequences for society. The aim of this project was to create the first Ukrainian recommendations for the diagnosis, prevention and treatment of osteoporosis in men in order to improve the awareness of the medical community and increase the efficiency of medical care. To achieve this goal, a multidisciplinary expert group was created, which, based on a comprehensive analysis of modern literature sources and their assessment using the GRADE tool, formulated and successfully voted on 19 statements regarding risk factors, screening, diagnosis, non-pharmacological and pharmacological treatment of osteoporosis in men. The authors proposed an algorithm for the management of osteoporosis in men depending on age and the risk of osteoporotic fractures. The statements of these recommendations are supported by the Ukrainian Association of Osteoporosis and are recommended for use at different levels of providing medical care by health professionals of various specialties.
Ключевые слова
остеопороз; чоловіки; рекомендації; діагностика; профілактика; лікування
osteoporosis; men; recommendations; diagnosis; prevention; treatment
Для ознакомления с полным содержанием статьи необходимо оформить подписку на журнал.
Список литературы
1. International Osteoporosis Foundation. About osteoporosis. https://www.osteoporosis.foundation/health-professionals/about-osteoporosis.
2. WHO. Disorders of bone density and structure. In: International Statistical Classification of Diseases and Related Health Problems 10th Revision; Chapter XIII: Diseases of the musculoskeletal system and connective tissue. M80-M85. https://icd.who.int/browse10/2019/en#/M80.
3. Kanis JA, Norton N, Harvey NC, et al. SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos. 2021 Jun 2;16(1):82. doi: 10.1007/s11657-020-00871-9.
4. Katsoulis M, Benetou V, Karapetyan T, et al. Excess mortality after hip fracture in elderly persons from Europe and the USA: the CHANCES project. J Intern Med. 2017 Mar;281(3):300-310. doi: 10.1111/joim.12586.
5. Sing C-W, Lin T-C, Bartholomew S, et al. Global epidemiology of hip fractures: secular trends in incidence rate, post-fracture treatment, and all-cause mortality. J Bone Miner Res. 2023;38(6):1064-75. doi: 10.1002/jbmr.4821.
6. Zubach O, Grygorieva N, Povoroznyuk V. 10-year mortality in patients after hip fractures. Georgian Med News. 2021 Jan;(310):19-23. Russian. PMID: 33658403.
7. Panahi N, Saeedi Moghaddam S, Fahimfar N, et al. Trend in global burden attributable to low bone mineral density in different WHO regions: 2000 and beyond, results from the Global Burden of Disease (GBD) study 2019. Endocr Connect. 2023 Sep 14;12(10):e230160. doi: 10.1530/EC-23-0160.
8. Borgstrm F, Karlsson L, Ortster G, et al. Fragility fractures in Europe: burden, management and opportunities. Arch Osteoporos. 2020;15:59. doi: 10.1007/s11657-020-0706-y.
9. Поворознюк В.В., Мусієнко А.С., Дзерович Н.І. Вікові особливості мінеральної щільності та якості кісткової тканини в чоловіків. Ортопедія, травматологія і протезування. 2015;3(600):66-70. http://nbuv.gov.ua/UJRN/OpTlP_2015_3_12.
10. Povoroznyuk VV, Grygorieva NV, Kanis JA, et al. Epidemiology of hip fracture and the development of FRAX in Ukraine. Arch Osteoporos. 2017 Dec;12(1):53. doi: 10.1007/s11657-017-0343-2.
11. Розподіл постійного населення України за статтю та віком на 1 січня 2022 р. За редакцією М. Тімоніної. Державна служба статистики України, Київ, 2022. https://www.ukrstat.gov.ua/druk/publicat/kat_u/2022/zb/06/roz_nas22.pdf.
12. Bandeira L, Silva BC, Bilezikian JP. Male osteoporosis. Arch Endocrinol Metab. 2022 Nov 11;66(5):739-747. doi: 10.20945/2359-3997000000563.
13. Головач И.Ю., Егудина Е.Д. Остеопороз у мужчин: состояние проблемы, факторы риска, диагностика, современные подходы к лечению. Травма. 2018;19(5):5-19. doi: 10.22141/1608-1706.5.19.2018.146639.
14. Bjornsdottir S, Clarke BL, Mannstadt M, et al. Male osteoporosis: what are the causes, diagnostic challenges, and ma–nagement. Best Pract Res Clin Rheumatol. 2022;36(3):101766. doi: 10.1016/j.berh.2022.101766.
15. Infante M, Caprio M, Fabbri A. Introduction: causes and risk factors for male osteoporosis. In: Ferlin A, Migliaccio S, editors. Male osteoporosis. Trends in andrology and sexual medicine. Cham: Springer, 2020. doi: 10.1007/978-3-319-96376-1_5.
16. Mafi Golchin M, Heidari L, Ghaderian SM, Akhavan-Niaki H. Osteoporosis: A Silent Disease with Complex Genetic Contribution. J Genet Genomics. 2016 Feb 20;43(2):49-61. doi: 10.1016/j.jgg.2015.12.001.
17. Golds G, Houdek D, Arnason T. Male hypogonadism and osteoporosis: the effects, clinical consequences, and treatment of testosterone deficiency in bone health. Int J Endocrinol. 2017;4602129. doi: 10.1155/2017/4602129.
18. Varsavsky M, Romero Muoz M, vila Rubio V, et al. Consensus document on osteoporosis in males. Endocrinologa, Diabetes y Nutricin (English ed.). 2018;65:9-16. doi: 10.1016/j.endien.2017.12.003.
19. Loures MAR, Zerbini CAF, Danowski JS, et al. Guidelines of the Brazilian Society of Rheumatology for the diagnosis and treatment of osteoporosis in men. Rev Bras Reumatol Engl Ed. 2017;57(Suppl 2):497-514. English, Portuguese. doi: 10.1016/j.rbre.2017.07.003.
20. Bouvard B, Briot K, Legrand E, et al. Recommandations franaises de la prise en charge et du traitement de l’ostoporose masculine. Rev Rhum. 2021;88(3):173-82. doi: 10.1016/j.rhum.2021.02.024.
21. Fuggle NR, Beaudart C, Bruyre O, et al. Evidence-Based Guideline for the management of osteoporosis in men. Nat Rev Rheumatol. 2024 Apr;20(4):241-251. doi: 10.1038/s41584-024-01094-9.
22. Rochira V, Antonio L, Vanderschueren D. EAA clinical guideline on management of bone health in the andrological outpatient clinic. Andrology. 2018;6(2):272-85. doi: 10.1111/andr.12470.
23. Huang CF, Ho CJ, Lin SY, et al. Asia-Pacific consensus for the management of osteoporosis in men. Osteoporos Int. 2025 Jul;36(7):1105-1114. doi: 10.1007/s00198-025-07559-1.
24. Gregson CL, Armstrong DJ, Avgerinou C, et al.; National Osteoporosis Guideline Group (NOGG). The 2024 UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2025;20:119. doi: 10.1007/s11657-025-01588-3.
25. LeBoff MS, Greenspan SL, Insogna KL, et al. The clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022 Oct;33(10):2049-2102. doi: 10.1007/s00198-021-05900-y.
26. World Health Organization. WHO handbook for guideline development, 2nd ed. Switzerland: World Health Organization, 2014. 167 p.
27. Guyatt GH, Oxman AD, Vist GE, et al; GRADE Wor–king Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008 Apr 26;336(7650):924-6. doi: 10.1136/bmj.39489.470347.AD.
28. Посібник для розробників клінічних рекомендацій/медичних стандартів (скорочений варіант). Новічкова О., Росс Г., Степаненко А. (загальна редакція). Київ, 2007. 71 с. https://dec.gov.ua/wp-content/uploads/2019/11/prs.pdf.
29. Watts NB, Adler RA, Bilezikian JP, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012 Jun;97(6):1802-22. doi: 10.1210/jc.2011-3045.
30. Povoroznyuk V, Johansson H, Grygorieva N, et al. Ukrainian FRAX version in the male osteoporosis management. Pain, Joints, Spine. 2021;11(2):53-61. doi: 10.22141/2224-1507.11.2.2021.236563.
31. ISDC. 2023 ISCD Official Positions. Adults. https://iscd.org/official-positions-2023.
32. Anupama S, Lim SY, Bolster MB. Updates on the role of DXA in the evaluation and monitoring of osteoporosis. Curr Rheumatol Rep. 2025 Nov 1;27(1):38. doi: 10.1007/s11926-025-01205-9.
33. Binkley N, Adler R, Bilezikian JP. Osteoporosis diagnosis in men: the T-score controversy revisited. Curr Osteoporos Rep. 2014 Dec;12(4):403-9. doi: 10.1007/s11914-014-0242-z.
34. De Laet CE, Van Hout BA, Burger H, Weel AE, Hofman A, Pols HA. Hip fracture prediction in elderly men and wo–men: validation in the Rotterdam study. J Bone Miner Res. 1998 Oct;13(10):1587-93. doi: 10.1359/jbmr.1998.13.10.1587.
35. Kanis JA, McCloskey EV, Harvey NC, et al. The need to distinguish intervention thresholds and diagnostic thre-sholds in the management of osteoporosis. Osteoporos Int. 2023 Jan;34(1):1-9. doi: 10.1007/s00198-022-06567-9.
36. Mousavi SZ, Moshfeghinia R, Vardanjani HM, Sasani MR. Opportunistic screening of osteoporosis by CT scan compared to DXA: A systematic review and meta-analysis. Clinical Imaging. 2025;118:110372. doi: 10.1016/j.clinimag.2024.110372.
37. Wang L, Diacinti D, Diacinti D, Minisola S, Yajun L. The diagnosis of osteoporosis, including opportunistic computed tomography: a narrative review. Gerontology. 2025;71(6):453-460. doi: 10.1159/000545961.
38. Gausden EB, Nwachukwu BU, Schreiber JJ, Lorich DG, Lane JM. Opportunistic use of CT imaging for osteoporosis screening and bone density assessment: a qualitative syste–matic review. J Bone Joint Surg Am. 2017;99(18):1580-90. doi: 10.2106/JBJS.16.00749.
39. Bromiley PA, Clark EM, Poole KE. Computer-aided diagnostic systems for osteoporotic vertebral fracture detection: opportunities and challenges. J Bone Miner Res. 2020 Dec;35(12):2305-2306. doi: 10.1002/jbmr.4205.
40. Howlett DC, Drinkwater KJ, Mahmood N, Illes J, Griffin J, Javaid K. Radiology reporting of osteoporotic vertebral fragility fractures on computed tomography studies: results of a UK national audit. Eur Radiol. 2020 Sep;30(9):4713-4723. doi: 10.1007/s00330-020-06845-2.
41. Hou Z, Gao Y, Ding S, Shao F, Zhang G. Diagnostic efficiency of chest CT for opportunistic screening for osteoporosis and low BMD in postmenopausal women. Sci Rep. 2025;15:32739. doi: 10.1038/s41598-025-16113-2.
42. Ye K, Qi J, Fan J, et al. Coronal CT attenuation measurement for osteoporosis screening at the proximal femur: a comparative study with the axial approach. Diagnostics. 2025;15(21):2794. doi: 10.3390/diagnostics15212794.
43. Zhu Y, Triphuridet N, Yip R, et al. Opportunistic CT screening of osteoporosis on thoracic and lumbar spine: a meta-analysis. Clin Imaging. 2021 Dec:80:382-390. doi: 10.1016/j.clinimag.2021.08.005.
44. Jiancheng Yang,∙Yuhong Zeng, Wei Yu. Criteria for osteoporosis diagnosis: a systematic review and meta-analysis of osteoporosis diagnostic studies with DXA and QCT. eClinicalMe–dicine. 2025;83:10324. doi: 10.1016/j.eclinm.2025.103244.
45. Hiberg MP, Rubin KH, Hermann AP, Brixen K, Abrahamsen B. Diagnostic devices for osteoporosis in the general population: A systematic review. Bone. 2016 Nov;92:58-69. doi: 10.1016/j.bone.2016.08.011.
46. McCloskey EV, Kanis JA, Odn A, et al. Predictive ability of heel quantitative ultrasound for incident fractures: an indivi–dual-level meta-analysis. Osteoporos Int. 2015 Jul;26(7):1979-87. doi: 10.1007/s00198-015-3072-7.
47. Escobio-Prieto I, Blanco-Daz M, Pinero-Pinto E, et al. Quantitative ultrasound and bone health in elderly people, a systematic review. Biomedicines. 2023 Apr 13;11(4):1175. doi: 10.3390/biomedicines11041175.
48. Harvey NC, Gler CC, Binkley N, et al. Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice. Bone. 2015 Sep;78:216-24. doi: 10.1016/j.bone.2015.05.016.
49. Поворознюк В.В., Дзерович Н.І., Ханс Д. Показник якості трабекулярної кісткової тканини в клінічній практиці (огляд літератури). Ортопедия, травматология и протезирование. 2015;2:126-136. doi: 10.15674/0030-598720152126-136.
50. Kaloudis E-Th. Trabecular bone score for the evaluation of fracture risk: A literature review. JRPMS. 2022;6(4):121-127. doi: 10.22540/JRPMS-06-121.
51. McCloskey EV, Odn A, Harvey NC, et al. A meta-ana–lysis of trabecular bone score in fracture risk prediction and its relationship to FRAX. J Bone Miner Res. 2016 May;31(5):940-8. doi: 10.1002/jbmr.2734.
52. Shevroja E, Reginster JY, Lamy O, et al. Update on the clinical use of trabecular bone score (TBS) in the management of osteoporosis: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases –(ESCEO), and the International Osteoporosis Foundation (IOF) under the auspices of WHO Collaborating Center for Epidemio–logy of Musculoskeletal Health and Aging. Osteoporos Int. 2023 Sep;34(9):1501-1529. doi: 10.1007/s00198-023-06817-4.
53. Hans D, teov E, Lamy O. The trabecular bone score (TBS) complements DXA and the FRAX as a fracture risk assessment tool in routine clinical practice. Curr Osteoporos Rep. 2017 Dec;15(6):521-531. doi: 10.1007/s11914-017-0410-z.
54. Shevroja E, Lamy O, Kohlmeier L, Koromani F, Riva–deneira F, Hans D. Use of trabecular bone score (TBS) as a complementary approach to dual-energy X-ray absorptio–metry (DXA) for fracture risk assessment in clinical practice. J Clin Densitom. 2017 Jul-Sep;20(3):334-345. doi: 10.1016/j.jocd.2017.06.019.
55. Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res. 2005 Jul;20(7):1185-94. doi: 10.1359/JBMR.050304.
56. Salari N, Darvishi N, Bartina Y, et al. Global prevalence of osteoporosis among the world older adults: a comprehensive systematic review and meta-analysis. J Orthop Surg Res. 2021 Nov 13;16(1):669. doi: 10.1186/s13018-021-02821-8.
57. Kanis JA, Johansson H, McCloskey EV, et al. Previous fracture and subsequent fracture risk: a meta-analysis to update FRAX. Osteoporos Int. 2023 Dec;34(12):2027-2045. doi: 10.1007/s00198-023-06870-z.
58. McCloskey EV, Johansson H, Liu E, kesson KE, et al. Family history of fracture and fracture risk: a meta-analysis to update the FRAX® risk assessment tool. Osteoporos Int. 2025 Sep;36(9):1725-1741. doi: 10.1007/s00198-025-07607-w.
59. Harvey NC, Odn A, Orwoll E, et al. Falls predict fractures independently of FRAX probability: a meta-analysis of the osteoporotic fractures in men (MrOS) Study. J Bone Miner Res. 2018 Mar;33(3):510-516. doi: 10.1002/jbmr.3331.
60. Vandenput L, Johansson H, McCloskey EV, et al. A meta-analysis of previous falls and subsequent fracture risk in cohort studies. Osteoporos Int. 2024 Mar;35(3):469-494. doi: 10.1007/s00198-023-07012-1.
61. Harvey NC, Johansson H, McCloskey EV, et al. Body mass index and subsequent fracture risk: a meta-analysis to update FRAX. J Bone Miner Res. 2025 Sep 28;40(10):1144-1155. doi: 10.1093/jbmr/zjaf091.
62. Kaze AD, Rosen HN, Paik JM. A meta-analysis of the association between body mass index and risk of vertebral fracture. Osteoporos Int. 2018 Jan;29(1):31-39. doi: 10.1007/s00198-017-4294-7.
63. Xu Y, Bao Y, Wang M, Wu Q. Smoking and fracture risk in men: a meta-analysis of cohort studies, using both frequentist and Bayesian approaches. Sci Rep. 2022;12:9270. doi: 10.1038/s41598-022-13356-1.
64. Wu Z-J, Zhao P, Liu B, Yuan Z-C. Effect of Cigarette smoking on risk of hip fracture in men: a meta-analysis of 14 prospective cohort studies. PLoS One. 2016;11(12):e0168990. doi: 10.1371/journal.pone.0168990.
65. Asoudeh F, Salari-Moghaddam A, Lari-jani B, Esmaillzadeh A. A systematic review and meta-analysis of prospective cohort studies on the association between alcohol intake and risk of fracture. Crit Rev Food Sci Nutr. 2022;62(20):5623-5637. doi: 10.1080/10408398.2021.1888691.
66. Ke Y, Hu H, Zhang J, Yuan L, et al. Alcohol consumption and risk of fractures: a systematic review and dose-response meta-analysis of prospective cohort studies. Adv Nutr. 2023 Jul;14(4):599-611. doi: 10.1016/j.advnut.2023.03.008.
67. Godos J, Giampieri F, Chisari E, et al. Alcohol consumption, bone mineral density, and risk of osteoporotic fractures: a dose-response meta-analysis. Int J Environ Res Public Health. 2022 Jan 28;19(3):1515. doi: 10.3390/ijerph19031515.
68. Cheraghi Z, Doosti-Irani A, Almasi-Hashiani A, et al. The effect of alcohol on osteoporosis: A systematic review and meta-analysis. Drug Alcohol Depend. 2019 Apr 1;197:197-202. doi: 10.1016/j.drugalcdep.2019.01.025.
69. Harvey NC, Odn A, Orwoll E, et al. Measures of Physical performance and muscle strength as predictors of fracture risk independent of FRAX, falls, and aBMD: a meta-analysis of the Osteoporotic Fractures in Men (MrOS) Study. J Bone Miner Res. 2018 Dec;33(12):2150-2157. doi: 10.1002/jbmr.3556.
70. Harvey NC, Orwoll E, Kwok T, et al. Sarcopenia definitions as predictors of fracture risk independent of FRAX®, falls, and BMD in the osteoporotic fractures in men (MrOS) study: a meta-analysis. J Bone Miner Res. 2021 Jul;36(7):1235-1244. doi: 10.1002/jbmr.4293.
71. Charoenngam N, Rittiphairoj T, Ponvilawan B, et al. Bone fragility in hereditary connective tissue disorders: a systematic review and meta-analysis. Endocr Pract. 2023 Jul;29(7):589-600. doi: 10.1016/j.eprac.2023.02.003.
72. Ramrez J, Nieto-Gonzlez JC, Rodrguez RС, Castaeda S, Carmona L. Prevalence and risk factors for osteoporosis and fractures in axial spondyloarthritis: A systematic review and meta-analysis. Seminars in Arthritis and Rheumatism. 2018;48(1):44-52. doi: 10.1016/j.semarthrit.2017.12.001.
73. Harlianto NI, Ezzafzafi S, Foppen W, et al. The prevalence of vertebral fractures in diffuse idiopathic skeletal hyperostosis and ankylosing spondylitis: A systematic review and meta-analysis. N Am Spine Soc J. 2024 Jan 20;17:100312. doi: 10.1016/j.xnsj.2024.100312.
74. Yan F, Wu L, Lang J, Huang Z. Bone density and fracture risk factors in ankylosing spondylitis: a meta-analysis. Osteoporos Int. 2024 Jan;35(1):25-40. doi: 10.1007/s00198-023-06925-1.
75. Pray C, Feroz NI, Nigil Haroon N. Bone mineral density and fracture risk in ankylosing spondylitis: a meta-analysis. Calcif Tissue Int. 2017 Aug;101(2):182-192. doi: 10.1007/s00223-017-0274-3.
76. Kanis JA, Johansson H, McCloskey EV, et al. Rheumatoid arthritis and subsequent fracture risk: an individual person meta-analysis to update FRAX. Osteoporos Int. 2025 Apr;36(4):653-671. doi: 10.1007/s00198-025-07397-1.
77. Xue AL, Wu SY, Jiang L, Feng AM, Guo HF, Zhao P. Bone fracture risk in patients with rheumatoid arthritis: A meta-analysis. Medicine (Baltimore). 2017 Sep;96(36):e6983. doi: 10.1097/MD.0000000000006983.
78. Chen B, Cheng G, Wang H, Feng Y. Increased risk of vertebral fracture in patients with rheumatoid arthritis: A meta-analysis. Medicine (Baltimore). 2016 Nov;95(45):e5262. doi: 10.1097/MD.0000000000005262.
79. Jin S, Hsieh E, Peng L, et al. Incidence of fractures among patients with rheumatoid arthritis: a systematic review and meta-analysis. Osteoporos Int. 2018 Jun;29(6):1263-1275. doi: 10.1007/s00198-018-4473-1.
80. Moshayedi S, Tasorian B, Almasi-Hashiani A. The prevalence of osteoporosis in rheumatoid arthritis patient: a systematic review and meta-analysis. Sci Rep. 2022;12:15844. doi: 10.1038/s41598-022-20016-x.
81. Wang X, Yan S, Liu C, Xu Y, et al. Fracture risk and bone mineral density levels in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Osteoporos Int. 2016 Apr;27(4):1413-1423. doi: 10.1007/s00198-015-3449-7.
82. Drake MT, Murad MH, Mauck KF, et al. Clinical review. Risk factors for low bone mass-related fractures in men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2012 Jun;97(6):1861-70. doi: 10.1210/jc.2011-3058.
83. Moayeri A, Mohamadpour M, Mousavi SF, Shirzadpour E, Mohamadpour S, Amraei M. Fracture risk in patients with type 2 diabetes mellitus and possible risk factors: a syste–matic review and meta-analysis. Ther Clin Risk Manag. 2017 Apr 11;13:455-468. doi: 10.2147/TCRM.S131945.
84. Liu X, Chen F, Liu L, Zhang Q. Prevalence of osteoporosis in patients with diabetes mellitus: a systematic review and meta-analysis of observational studies. BMC endocrine disorders. 2023;23(1):1. doi: 10.1186/s12902-022-01260-8.
85. Wang H, Ba Y, Xing Q, Du J-L. Diabetes mellitus and the risk of fractures at specific sites: a meta-analysis. BMJ Open. 2019;9:e024067. doi: 10.1136/bmjopen-2018-024067.
86. Blum MR, Bauer DC, Collet TH, et al.; Thyroid Stu–dies Collaboration. Subclinical thyroid dysfunction and fracture risk: a meta-analysis. JAMA. 2015 May 26;313(20):2055-65. doi: 10.1001/jama.2015.5161.
87. Zhang T, Pan W, Huang K, Qiu J, Zhang W, Yang J. Association of subclinical thyroid dysfunction with the risk of vertebral fracture: a meta-analysis of prospective cohort studies. Annals of Medicine. 2025 Dec;57(1):2558122. doi: 10.1080/07853890.2025.2558122.
88. Zhu H, Zhang J, Wang J. et al. Association of subclinical thyroid dysfunction with bone mineral density and fracture: a meta-analysis of prospective cohort studies. Endocrine. 2020;67:685-698. doi: 10.1007/s12020-019-02110-9.
89. Narayanan N, Palui R, Merugu C, Kar SS, et al. The risk of fractures in primary hyperparathyroidism: a meta-ana–lysis. JBMR Plus. 2021 Mar 16;5(4):e10482. doi: 10.1002/jbm4.10482.
90. Shahbaz Y, Jamalafrouz Z, Hesari N, et al. Risk of bone fractures in patients with primary hyperparathyroidism: a systematic review and meta-analysis. Journal of Parathyroid –Disease. 2024;12:e12262. doi: 10.34172/jpd.2024.12262.
91. Pal R, Bhadada SK, Mukherjee S, Banerjee M, Kumar A. Fracture risk in hypoparathyroidism: a systematic review and meta-analysis. Osteoporos Int. 2021 Nov;32(11):2145-2153. doi: 10.1007/s00198-021-05966-8.
92. Mazziotti GBE, Maffezzoni F, et al. Bone turnover, bone mineral density, and fracture risk in acromegaly: A Meta-Analysis. J Clin Endocrinol Metab. 2015;100(2):384-94. doi: 10.1210/jc.2014-2937.
93. Hao L, Mu S, Yin J, Liu J. A meta-analysis of the risk of osteoporotic fractures in inflammatory bowel disease. Adv Clin Exp Med. 2024 Apr;33(4):327-333. doi: 10.17219/acem/168684.
94. Szafors P, Che H, Barnetche T, et al. Risk of fracture and low bone mineral density in adults with inflammatory bowel diseases. A systematic literature review with meta-analysis. Osteoporos Int. 2018 Nov;29(11):2389-2397. doi: 10.1007/s00198-018-4586-6.
95. Marzban Abbas Abadi M, Emadian ST, Zamani M, Khalilizad M. Prevalence of osteoporosis in patients with inflammatory bowel disease: a systematic review and meta-analysis. J Health Popul Nutr. 2025 May 29;44(1):178. doi: 10.1186/s41043-025-00946-8.
96. Liang J, Meng WD, Yang JM, et al. The association between liver cirrhosis and fracture risk: A systematic review and meta-analysis. Clin Endocrinol (Oxf). 2018 Oct;89(4):408-413. doi: 10.1111/cen.13762.
97. Shirinezhad A, Eshlaghi FM, Salabat D, et al. Prevalent osteoporosis and fracture risk in patients with hepatic cirrhosis: a systematic review and meta-analysis. BMC Gastroenterol. 2025 Feb 25;25(1):115. doi: 10.1186/s12876-025-03720-6.
98. Lupoli R, Di Minno A, Spadarella G, et al. The risk of osteoporosis in patients with liver cirrhosis: a meta-analysis of literature studies. Clin Endocrinol (Oxf). 2016 Jan;84(1):30-8. doi: 10.1111/cen.12780.
99. Kang J, Gopakumar H, Puli SR. Prevalence of osteoporosis in cirrhosis: a systematic review and meta-analysis. Cureus. 2023 Jan 12;15(1):e33721. doi: 10.7759/cureus.33721.
100. Mortensen SJ, Mohamadi A, Wright CL, et al. Medications as a risk factor for fragility hip fractures: a systematic review and meta-analysis. Calcif Tissue Int. 2020 Jul;107(1):1-9. doi: 10.1007/s00223-020-00688-1.
101. Li L, Bensing S, Falhammar H. Rate of fracture in patients with glucocorticoid replacement therapy: a systematic review and meta-analysis. Endocrine. 2021 Oct;74(1):29-37. doi: 10.1007/s12020-021-02723-z.
102. Loke YK, Gilbert D, Thavarajah M, Blanco P, Wilson AM. Bone mineral density and fracture risk with long-term use of inhaled corticosteroids in patients with asthma: systematic review and meta-analysis. BMJ Open. 2015 Nov 24;5(11):e008554. doi: 10.1136/bmjopen-2015-008554.
103. Peng S, Tan C, Du L, et al. Effect of fracture risk in inhaled corticosteroids in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. BMC Pulm Med. 2023;23:304. doi: 10.1186/s12890-023-02602-5.
104. Ruanpeng D, Ungprasert P, Sangtian J, Harind-hanavudhi T. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis. Diabetes Metab Res Rev. 2017 Sep;33(6). doi: 10.1002/dmrr.2903.
105. Chai S, Liu F, Yang Z, et al. Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis combining 177 randomized controlled trials with a median follow-up of 26 weeks. Front Pharmacol. 2022 Jul 1;13:825417. doi: 10.3389/fphar.2022.825417.
106. Mercurio M, de Filippis R, Spina G, et al. The use of antidepressants is linked to bone loss: A systematic review and meta-analysis. Orthop Rev (Pavia). 2022 Oct 13;14(6):38564. doi: 10.52965/001c.38564.
107. Poly TN, Islam MM, Yang HC, Li YJ. Association between benzodiazepines use and risk of hip fracture in the elderly people: A meta-analysis of observational studies. Joint Bone Spine. 2020 May;87(3):241-249. doi: 10.1016/j.jbspin.2019.11.003.
108. Zhang YS, Zheng YD, Yuan Y, Chen SC, Xie BC. Effects of anti-diabetic drugs on fracture risk: a systematic review and network meta-analysis. Front Endocrinol (Lausanne). 2021 Oct 14;12:735824. doi: 10.3389/fendo.2021.735824.
109. Teng Z, Zhu Y, Wu F, et al. Opioids Contribute to Fracture Risk: A Meta-Analysis of 8 Cohort Studies. PLoS One. 2015;10(6):e0128232. doi: 10.1371/journal.pone.0128232.
110. Batteux B, Bennis Y, Bodeau S, et al. Associations between osteoporosis and drug exposure: A post-marketing study of the World Health Organization pharmacovigilance database (VigiBase®). Bone. 2021 Dec;153:116137. doi: 10.1016/j.bone.2021.116137.
111. Kanis JA, Johansson H, Harvey NC, McCloskey EV. A brief history of FRAX. Arch Osteoporos. 2018 Oct 31;13(1):118. doi: 10.1007/s11657-018-0510-0.
112. Поворознюк В.В., Григор’єва Н.В., Kanis J.A., McCloskey E.V., Johansson H. Українська версія FRAX: від створення до валідизації. Біль. Суглоби. Хребет. 2016;3(23):5-14. doi: 10.22141/2224-1507.3.23.2016.85000.
113. Povoroznyuk V, Grygorieva N, Johansson H, et al. FRAX-Based Intervention Thresholds for Osteoporosis Treatment in Ukraine. J Osteoporos. 2021 Jun 10;2021:2043479. doi: 10.1155/2021/2043479.81.
114. Schini M, Johansson H, Harvey NC, Lorentzon M, Kanis JA, McCloskey EV. An overview of the use of the fracture risk assessment tool (FRAX) in osteoporosis. J Endocrinol Invest. 2024 Mar;47(3):501-511. doi: 10.1007/s40618-023-02219-9.
115. Harvey NC, Johansson H, Odn A, et al. FRAX predicts incident falls in elderly men: findings from MrOs Sweden. Osteoporos Int. 2016 Jan;27(1):267-74. doi: 10.1007/s00198-015-3295-7.
116. Sugimoto T, Matsumoto T, Hosoi T, et al. Efficacy of denosumab co-administered with vitamin D and Ca by baseline vitamin D status. J Bone Miner Metab. 2020 Nov;38(6):848-858. doi: 10.1007/s00774-020-01119-9.166.
117. Lu K, Shi Q, Gong YQ, Li C. Association between vitamin D and zoledronate-induced acute-phase response fever risk in osteoporotic patients. Front Endocrinol (Lausanne). 2022 Oct 10;13:991913. doi: 10.3389/fendo.2022.991913.
118. Grygorieva NV, Solonenko TY, Musiienko AS, Bystrytska MA. Vitamin D deficiency in Ukraine: current evidence. BMC Nutr. 2023 Mar 14;9(1):49. doi: 10.1186/s40795-023-00706-z.
119. McBride JA, Carson CC, Coward RM. Diagnosis and management of testosterone deficiency. Asian J Androl. 2015 Mar-Apr;17(2):177-86. doi: 10.4103/1008-682X.143317.
120. Bhasin S, Pencina M, Jasuja GK, et al. Reference ran–ges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab. 2011 Aug;96(8):2430-9. doi: 10.1210/jc.2010-3012.
121. Lunenfeld B, Mskhalaya G, Zitzmann M, et al. Re–commendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male. 2015 Mar;18(1):5-15. doi: 10.3109/13685538.2015.1004049.
122. Mellstrm D, Johnell O, Ljunggren O, et al. Free testosterone is an independent predictor of BMD and prevalent fractures in elderly men: MrOS Sweden. Journal of Bone and Mineral Research. 2006;21(4):529-535. doi.org/10.1359/jbmr.060110.
123. Meier C, Nguyen TV, Handelsman DJ, et al. Endo–genous sex hormones and incident fracture risk in older men: the Dubbo Osteoporosis Epidemiology Study. Arch Intern Med. 2008 Jan 14;168(1):47-54. doi: 10.1001/archinternmed.2007.2.
124. Luo Z, Feng A, Tyurin A, et al. Testosterone, sex hormone-binding globulin, and fracture risk in men: evidence from observational and Mendelian randomization analyses. Osteoporos Int. 2025 Oct;36(10):1977-1986. doi: 10.1007/s00198-025-07620-z.
125. Vandenput L, Mellstrm D, Laughlin GA, et al. Low testosterone, but not estradiol, is associated with incident falls in older men: the international MrOS Study. J Bone Miner Res. 2017 Jun;32(6):1174-1181. doi: 10.1002/jbmr.3088.
126. Johansson H, Odn A, Kanis JA, et al.; IFCC-IOF Joint Working Group on standardisation of biochemical markers of bone turnover. a meta-analysis of reference markers of bone turnover for prediction of fracture. Calcif Tissue Int. 2014 May;94(5):560-7. doi: 10.1007/s00223-014-9842-y.
127. Hong L, Liu D, Wu F, Wang M, Cen Y, Ma L. Correlation between bone turnover markers and bone mineral density in patients undergoing long-term anti-osteoporosis treatment: a systematic review and meta-analysis. Applied Sciences. 2020;10(3):832. doi: 10.3390/app10030832.
128. Lorentzon M, Branco J, Brandi ML, et al. Algorithm for the use of biochemical markers of bone turnover in the diagnosis, assessment, and follow-up of treatment for osteoporosis. Adv Ther. 2019 Oct;36(10):2811-2824. doi: 10.1007/s12325-019-01063-9.
129. Eastell R, Pigott T, Gossiel F, Naylor KE, Walsh JS, Peel NFA. Diagnosis of endocrine disease: Bone turnover markers: are they clinically useful? Eur J Endocrinol. 2018 Jan;178(1):R19-R31. doi: 10.1530/EJE-17-0585.
130. Schini M, Vilaca T, Gossiel F, Salam S, Eastell R. Bone Turnover Markers: Basic Biology to Clinical Applications. Endocr Rev. 2023 May 8;44(3):417-473. doi: 10.1210/endrev/bnac031.
131. Fisher A, Fisher L, Srikusalanukul W, Smith PN. Bone turnover status: classification model and clinical implications. Int J Med Sci. 2018 Feb 1;15(4):323-338. doi: 10.7150/ijms.22747.
132. Mortensen SJ, Beeram I, Florance J, et al. Modifiable lifestyle factors associated with fragility hip fracture: a systematic review and meta-analysis. J Bone Miner Metab. 2021 Sep;39(5):893-902. doi: 10.1007/s00774-021-01230-5.
133. Clemson L, Stark S, Pighills AC, et al. Environmental interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev. 2023 Mar 10;3(3):CD013258. doi: 10.1002/14651858.CD013258.pub2.
134. Chen CC, Shen YM, Li SB, Huang SW, Kuo YJ, Chen YP. Association of coffee and tea intake with bone mineral density and hip fracture: a meta-analysis. Medicina (Kaunas). 2023 Jun 20;59(6):1177. doi: 10.3390/medicina59061177.
135. Zeng X, Su Y, Tan A, et al. The association of coffee consumption with the risk of osteoporosis and fractures: a systematic review and meta-analysis. Osteoporos Int. 2022 Sep;33(9):1871-1893. doi: 10.1007/s00198-022-06399-7.
136. Григор’єва Н.В., Дєдух Н.В., Парубець М.М., Бистрицька М.А. Постіммобілізаційний остеопороз: огляд літератури та серія клінічних випадків. Біль. Суглоби. Хребет. 2022;12(3):94-107. doi: 10.22141/pjs.12.3.2022.335.
137. Cunningham C, O’Sullivan R, Caserotti P, Tully MA. Consequences of physical inactivity in older adults: A systematic review of reviews and meta-analyses. Scand J Med Sci Sports. 2020 May;30(5):816-827. doi: 10.1111/sms.13616.
138. Vilenskyi A, Grygorieva N, Stefiuk O, et al. Bone mi–neral density and bone turnover markers in war veterans after lower limb amputation. Pain. Joints. Spine. 2025;15(4):157-165. doi: 10.22141/pjs.15.4.2025.480.
139. Kast S, Shojaa M, Kohl M, et al. Effects of different exercise intensity on bone mineral density in adults: a comparative systematic review and meta-analysis. Osteoporos Int. 2022 Aug;33(8):1643-1657. doi: 10.1007/s00198-022-06329-7.
140. Schinzel E, Kast S, Kohl M, et al. The effect of aqua–tic exercise on bone mineral density in older adults. A systematic review and meta-analysis. Front Physiol. 2023 Mar 13;14:1135663. doi: 10.3389/fphys.2023.1135663.
141. Hoffmann I, Kohl M, von Stengel S, et al. Exercise and the prevention of major osteoporotic fractures in adults: a systematic review and meta-analysis with special emphasis on intensity progression and study duration. Osteoporos Int. 2023 Jan;34(1):15-28. doi: 10.1007/s00198-022-06592-8.
142. Hoffmann I, Shojaa M, Kohl M, et al. Exercise reduces the number of overall and major osteoporotic in adults. Does supervision make a difference? systematic review and meta-analysis. J Bone Miner Res. 2022 Nov;37(11):2132-2148. doi: 10.1002/jbmr.4683.
143. Pantouvaki A, Patelarou E, Kastanis G, Alpantaki K, Sfakianakis MZ. The effect of an exercise-based rehabilitation programme in functional recovery and prevention of secondary falls after a hip fracture in older adults: A systematic review. J Frailty Sarcopenia Falls. 2023 Jun 1;8(2):118-126. doi: 10.22540/JFSF-08-118.
144. Gibbs JC, MacIntyre NJ, Ponzano M, et al. Exercise for improving outcomes after osteoporotic vertebral fracture. Cochrane Database Syst Rev. 2019 Jul 5;7(7):CD008618. doi: 10.1002/14651858.CD008618.pub3.
145. Sherrington C, Fairhall NJ, Wallbank GK, et al. Exercise for preventing falls in older people living in the community. Cochrane Database Syst Rev. 2019 Jan 31;1(1):CD012424. doi: 10.1002/14651858.CD012424.pub2.
146. Huang ZG, Feng YH, Li YH, Lv CS. Systematic review and meta-analysis: Tai Chi for preventing falls in older adults. BMJ Open. 2017 Feb 6;7(2):e013661. doi: 10.1136/bmjopen-2016-013661.
147. Lomas-Vega R, Obrero-Gaitn E, Molina-Ortega FJ, Del-Pino-Casado R. Tai Chi for risk of falls. A meta-analysis. J Am Geriatr Soc. 2017 Sep;65(9):2037-2043. doi: 10.1111/jgs.15008.
148. Chen W, Li M, Li H, Lin Y, Feng Z. Tai Chi for fall prevention and balance improvement in older adults: a syste–matic review and meta-analysis of randomized controlled trials. Front Public Health. 2023 Sep 1;11:1236050. doi: 10.3389/fpubh.2023.1236050.
149. Kweh BTS, Lee HQ, Tan T, et al. Role of spinal orthoses in osteoporotic vertebral fractures of the elderly population (age 60 years or older): systematic review. Global Spine J. 2021 Jul;11(6):975-987. doi: 10.1177/2192568220948036.
150. Pieroh P, Spiegl UJA, Vlker A, et al.; Spine Section of the German Society for Orthopaedics and Trauma. Spinal orthoses in the treatment of osteoporotic thoracolumbar vertebral fractures in the elderly: a systematic review with quantitative quality assessment. Global Spine J. 2023 Apr;13(1_suppl):59S-72S. doi: 10.1177/21925682221130048.
151. Jin YZ, Lee JH. Effect of brace to osteoporotic vertebral fracture: a meta-analysis. J Korean Med Sci. 2016 Oct;31(10):1641-9. doi: 10.3346/jkms.2016.31.10.1641.
152. Furrer PR, Hodel S, Wanivenhaus F, Grubhofer F, Farshad M. Compliance with wearing a thoracolumbar orthosis in nonoperative treatment of osteoporotic vertebral fractures: a prospective sensor-controlled study. Spine J. 2023 Mar;23(3):433-439. doi: 10.1016/j.spinee.2022.11.009.
153. Webster J, Dalla Via J, Langley C, Smith C, Sale C, Sim M. Nutritional strategies to optimise musculoskeletal health for fall and fracture prevention: Looking beyond calcium, vitamin D and protein. Bone Rep. 2023 May 5;19:101684. doi: 10.1016/j.bonr.2023.101684.
154. Webster J, Rycroft CE, Greenwood DC, Cade JE. Dietary risk factors for hip fracture in adults: An umbrella review of meta-analyses of prospective cohort studies. PLoS One. 2021 Nov 10;16(11):e0259144. doi: 10.1371/journal.pone.0259144.
155. Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium. Dietary Refe–rence Intakes for Calcium and Vitamin D. Ross AC, Taylor CL, Yaktine AL, Del Valle HB, editors. Washington (DC): National Academies Press (US), 2011. PMID: 21796828.
156. On the approval of the norms of physiological needs of the population of Ukraine in basic food substances and energy. Order of the Ministry of Health of Ukraine (No 1073, 03.09.2017). https://zakon.rada.gov.ua/laws/show/z1206-17/ed20170903/stru.
157. Grygorieva N, Povoroznyuk V, Romanenko M, Sy–nieok L. Calcium intake in an adult Ukrainian population. Arch Osteoporos. 2020 Feb 23;15(1):23. doi: 10.1007/s11657-020-0712-0.
158. Demay MB, Pittas AG, Bikle DD, et al. Vitamin D for the prevention of disease: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2024 Jul 12;109(8):1907-1947. doi: 10.1210/clinem/dgae290.
159. Григор’єва Н.В., Солоненко Т.Ю., Мусієнко А.С. Дефіцит вітаміну D під час пандемії COVID-19 і війни в Україні. Біль. Суглоби. Хребет. 2023;13(1);7-14. doi: 10.22141/pjs.13.1.2023.352.
160. Tai V, Leung W, Grey A, Reid IR, Bolland MJ. Calcium intake and bone mineral density: systematic review and meta-analysis. BMJ. 2015 Sep 29;351:h4183. doi: 10.1136/bmj.h4183.
161. Bolland MJ, Leung W, Tai V, et al. Calcium intake and risk of fracture: systematic review. BMJ. 2015 Sep 29;351:h4580. doi: 10.1136/bmj.h4580.
162. Bolland MJ, Grey A, Avenell A. Effects of vitamin D supplementation on musculoskeletal health: a systematic review, meta-analysis, and trial sequential analysis. Lancet Diabetes Endocrinol. 2018 Nov;6(11):847-858. doi: 10.1016/S2213-8587(18)30265-1.
163. Yao P, Bennett D, Mafham M, et al. Vitamin D and calcium for the prevention of fracture: a systematic review and meta-analysis. JAMA Netw Open. 2019 Dec 2;2(12):e1917789. doi: 10.1001/jamanet-workopen.2019.17789.
164. Kong SH, Jang HN, Kim JH, Kim SW, Shin CS. Effect of vitamin D supplementation on risk of fractures and falls according to dosage and interval: a meta-analysis. Endocrinol Metab (Seoul). 2022 Apr;37(2):344-358. doi: 10.3803/EnM.2021.1374.
165. Thanapluetiwong S, Chewcharat A, Takkavatakarn K, Praditpornsilpa K, Eiam-Ong S, Susantitaphong P. Vitamin D supplement on prevention of fall and fracture: a meta-analysis of randomized controlled trials. Medicine (Baltimore). 2020 Aug 21;99(34):e21506. doi: 10.1097/MD.0000000000021506.
166. Zhao JG, Zeng XT, Wang J, Liu L. Association between calcium or vitamin D supplementation and fracture incidence in community-dwelling older adults: a systematic review and meta-analysis. JAMA. 2017 Dec 26;318(24):2466-2482. doi: 10.1001/jama.2017.19344.
167. Weaver CM, Alexander DD, Boushey CJ, et al. Calcium plus vitamin D supplementation and risk of fractures: an updated meta-analysis from the National Osteoporosis Foundation. Osteoporos Int. 2016 Jan;27(1):367-76. doi: 10.1007/s00198-015-3386-5.
168. Григор’єва Н.В., Тронько М.Д., Коваленко В.М. та ін. Діагностика, профілактика та лікування дефіциту вітаміну D у дорослих: Консенсус українських експертів. Біль. Суглоби. Хребет. 2023;13(2):60-76. doi: 10.22141/pjs.13.2.2023.368.
169. Sahni S, Mangano KM, Tucker KL, Kiel DP, Casey VA, Hannan MT. Protective association of milk intake on the risk of hip fracture: results from the Framingham Original Cohort. J Bone Miner Res. 2014 Aug;29(8):1756-62. doi: 10.1002/jbmr.2219.
170. Hidayat K, Du X, Shi BM, Qin LQ. Systematic review and meta-analysis of the association between dairy consumption and the risk of hip fracture: critical interpretation of the currently available evidence. Osteoporos Int. 2020 Aug;31(8):1411-1425. doi: 10.1007/s00198-020-05383-3.
171. Bian S, Hu J, Zhang K, Wang Y, Yu M, Ma J. Dairy product consumption and risk of hip fracture: a systematic review and meta-analysis. BMC Public Health. 2018 Jan 22;18(1):165. doi: 10.1186/s12889-018-5041-5.
172. Mata-Martn P, Torrego-Ellacura M, Larrad-Sainz A, Fernndez-Prez C, Cuesta-Triana F, Rubio-Herrera M. Effects of milk and dairy products on the prevention of osteoporosis and osteoporotic fractures in Europeans and Non-Hispanic whites from North America: a systema–tic review and updated meta-analysis. Adv Nutr. 2019 May 1;10(suppl_2):S120-S143. doi: 10.1093/advances/nmy097.
173. Malmir H, Larijani B, Esmaillzadeh A. Consumption of milk and dairy products and risk of osteoporosis and hip fracture: a systematic review and meta-analysis. Crit Rev Food Sci Nutr. 2020;60(10):1722-1737. doi: 10.1080/10408398.2019.1590800.
174. Shams-White MM, Chung M, Du M, et al. Dietary protein and bone health: a systematic review and meta-analysis from the National Osteoporosis Foundation. Am J Clin Nutr. 2017 Jun;105(6):1528-1543. doi: 10.3945/ajcn.116.145110.
175. Wu AM, Sun XL, Lv QB, et al. The relationship between dietary protein consumption and risk of fracture: a subgroup and dose-response meta-analysis of prospective cohort studies. Sci Rep. 2015 Mar 16;5:9151. doi: 10.1038/srep09151.
176. Wallace TC, Frankenfeld CL. Dietary protein intake above the current RDA and bone health: a systematic review and meta-analysis. J Am Coll Nutr. 2017 Aug;36(6):481-496. doi: 10.1080/07315724.2017.1322924.
177. Groenendijk I, den Boeft L, van Loon LJC, de Groot LCPGM. High versus low dietary protein intake and bone health in older adults: a systematic review and meta-analysis. Comput Struct Biotechnol J. 2019 Jul 22;17:1101-1112. doi: 10.1016/j.csbj.2019.07.005.
178. Zeraattalab-Motlagh S, Mortazavi AS, Ghoreishy SM, Mohammadi H. Association between total and animal proteins with risk of fracture: A systematic review and dose-response meta-analysis of cohort studies. Osteoporos Int. 2024 Jan;35(1):11-23. doi: 10.1007/s00198-023-06948-8.
179. Fung TT, Meyer HE, Willett WC, Feskanich D. Protein intake and risk of hip fractures in postmenopausal women and men age 50 and older. Osteoporos Int. 2017 Apr;28(4):1401-1411. doi: 10.1007/s00198-016-3898-7.
180. Rizzoli R, Biver E, Bonjour JP, et al. Benefits and safety of dietary protein for bone health: an expert consensus paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases and by the International Osteoporosis Foundation. Osteoporos Int. 2018 Sep;29(9):1933-1948. doi: 10.1007/s00198-018-4534-5.
181. Rinonapoli G, Ruggiero C, Meccariello L, Bisaccia M, Ceccarini P, Caraffa A. Osteoporosis in men: a review of an underestimated bone condition. Int J Mol Sci. 2021;22:2105. doi: 10.3390/ijms22042105.
182. Zhang Z, Kang D, Li H. The effects of testosterone on bone health in males with testosterone deficiency: a systematic review and meta-analysis. BMC Endocr Disord. 2020;20(1):33. doi: 10.1186/s12902-020-0509-6.
183. Corona G, Vena W, Pizzocaro A, et al. Testosterone supplementation and bone parameters: a systematic review and meta-analysis study. J Endocrinol Invest. 2022;45(5):911-926. doi: 10.1007/s40618-021-01702-5.
184. Kazahari H, Hoshiya H, Takahiko S, Ochiai R. The effectiveness and safety of testosterone replacement therapy in the musculoskeletal system of males with hypogonadism: a systematic review and meta-analysis. Journal of Clinical Question. 2024;1(3):148-158. doi: 10.69854/jcq.2024.0018/.
185. Junjie W, Dongsheng H, Lei S, Hongzhuo L, Changying S. Testosterone replacement therapy has limited effect on increasing bone mass density in older men: a meta-analysis. Curr Pharm Des. 2019;25(1):73-84. doi: 10.2174/1381612825666190206223244.
186. Kanakis GA, Pofi R, Goulis DG, et al. EMAS position statement: Testosterone replacement therapy in older men. Maturitas. 2023 Dec;178:107854. doi: 10.1016/j.maturitas.2023.107854.
187. Oryan A, Sahvieh S. Effects of bisphosphonates on osteoporosis: Focus on zoledronate. Life Sci. 2021 Jan 1;264:118681. doi: 10.1016/j.lfs.2020.118681.
188. Bellido T. Bisphosphonates for osteoporosis: from bench to clinic. J Clin Invest. 2024;134(6):e179942. doi: 10.1172/JCI179942.
189. Chen L, Wang G, Zheng F, Zhao H, Li H. Efficacy of bisphosphonates against osteoporosis in adult men: a meta-analysis of randomized controlled trials. Osteoporos Int. 2015 Sep;26(9):2355-63. doi: 10.1007/s00198-015-3148-4.
190. Beaudart C, Demonceau C, Sabico S, et al. Efficacy of osteoporosis pharmacological treatments in men: a systematic review and meta-analysis. Aging Clin Exp Res. 2023 Sep;35(9):1789-1806. doi: 10.1007/s40520-023-02478-9.
191. Zhou J, Wang T, Zhao X, Miller DR, Zhai S. Comparative efficacy of bisphosphonates to prevent fracture in men with osteoporosis: a systematic review with network meta-ana–lyses. Rheumatol Ther. 2016 Jun;3(1):117-128. doi: 10.1007/s40744-016-0030-6.
192. Al Lawati H, Al Busaidi S, Al Rawahi T, Al Lawati A, Kifah A, Das S. Alendronate for effective treatment of male osteoporosis: an insight. Curr Pharm Des. 2025;31(1):26-36. doi: 10.2174/0113816128310838240820065324.
193. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000 Aug 31;343(9):604-10. doi: 10.1056/NEJM200008313430902.
194. Xu Z. Alendronate for the treatment of osteoporosis in men: a meta-analysis of randomized controlled trials. Am J Ther. 2017 Mar/Apr;24(2):e130-e138. doi: 10.1097/MJT.0000000000000446.
195. McClung MR, Ebetino FH. History of risedronate. Bone. 2020 Aug;137:115407. doi: 10.1016/j.bone.2020.115407.
196. Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res. 2009 Apr;24(4):719-25. doi: 10.1359/jbmr.081214.
197. Ringe JD, Farahmand P, Faber H, Dorst A. Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study. Rheumatol Int. 2009 Jan;29(3):311-5. doi: 10.1007/s00296-008-0689-2.
198. Orwoll ES, Binkley NC, Lewiecki EM, Gruntmanis U, Fries MA, Dasic G. Efficacy and safety of monthly ibandronate in men with low bone density. Bone. 2010;46:970-976. doi: 10.1016/j.bone.2009.12.034.
199. Boonen S, Reginster JY, Kaufman JM, et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med. 2012 Nov 1;367(18):1714-23. doi: 10.1056/NEJMoa1204061.
200. Singh M, Gonegandla GS. Bisphosphonate-Induced Osteonecrosis of the Jaws (BIONJ). J Maxillofac Oral Surg. 2020 Jun;19(2):162-167. doi: 10.1007/s12663-019-01211-2.
201. Khan AA, Morrison A, Hanley DA et al.; International Task Force on Osteonecrosis of the Jaw. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015 Jan;30(1):3-23. doi: 10.1002/jbmr.2405.
202. Larsen MS, Schmal H. The enigma of atypical femoral fractures: A summary of current knowledge. EFORT Open Reviews. 2018;3(9):494-500. doi: 10.1302/2058-5241.3.170070.
203. Gedmintas L, Solomon DH, Kim SC. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res. 2013 Aug;28(8):1729-37. doi: 10.1002/jbmr.1893.
204. Kendler DL, Cosman F, Stad RK, Ferrari S. Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review. Adv Ther. 2022 Jan;39(1):58-74. doi: 10.1007/s12325-021-01936-y.
205. Chapurlat R. Effects and management of denosumab discontinuation. Joint Bone Spine. 2018 Oct;85(5):515-517. doi: 10.1016/j.jbspin.2017.12.013.184.
206. Orwoll E, Teglbjrg CS, Langdahl BL, et al. A rando–mized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab. 2012 Sep;97(9):3161-9. doi: 10.1210/jc.2012-1569.
207. Huang Z, Liao TC, Chuang AT, Shao SC, Lange J, Lin TC, et al. Denosumab and clinical outcomes among men with osteoporosis: a retrospective cohort study. Osteoporos Int. 2025 Mar;36(3):465-473. doi: 10.1007/s00198-024-07381-1.
208. Hauser B, Alonso N, Riches PL. Review of current real-world experience with teriparatide as treatment of osteoporosis in different patient groups. Journal of Clinical Medicine. 2021;10(7):1403. doi: 10.3390/jcm10071403.
209. Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003 Jan;18(1):9-17. doi: 10.1359/jbmr.2003.18.1.9.
210. Kaufman JM, Orwoll E, Goemaere S, et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int. 2005 May;16(5):510-6. doi: 10.1007/s00198-004-1713-3.
211. Minisola S, Cipriani C, Grotta GD, et al. Update on the safety and efficacy of teriparatide in the treatment of osteoporosis. Ther Adv Musculoskelet Dis. 2019 Oct 5;11:1759720X19877994. doi: 10.1177/1759720X19877994.
212. Czerwinski E, Cardona J, Plebanski R, et al. The Efficacy and Safety of Abaloparatide-SC in men with osteoporosis: a randomized clinical trial. J Bone Miner Res. 2022 Dec;37(12):2435-2442. doi: 10.1002/jbmr.4719.
213. Dhaliwal R, Kendler D, Saag K, et al. Response rates for lumbar spine, total hip, and femoral neck bone mineral density in men treated with abaloparatide: results from the ATOM study. JBMR Plus. 2024 Jan 27;8(2):ziae009. doi: 10.1093/jbmrpl/ziae009.
214. Mkinen VN, Slling AS, McClung M, Langdahl BL. Romosozumab for the treatment of osteoporosis — a systematic review. J Endocrinol Invest. 2025 Mar;48(3):547-572. doi: 10.1007/s40618-024-02469-1.
215. Lewiecki EM, Blicharski T, Goemaere S, et al. A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis. J Clin Endocrinol Metab. 2018 Sep 1;103(9):3183-3193. doi: 10.1210/jc.2017-02163.
216. Binkley N, Orwoll E, Chapurlat R, Langdahl BL, Scott BB, et al. Randomized, controlled trial to assess the safety and efficacy of odanacatib in the treatment of men with osteoporosis. Osteoporos Int. 2021 Jan;32(1):173-184. doi: 10.1007/s00198-020-05701-9.
217. Chen R, Chen C, Geng B, et al. Efficacy and safety of odanacatib for osteoporosis treatment: a systematic review and meta-analysis. Arch Osteoporos. 2023 May 11;18(1):67. doi: 10.1007/s11657-023-01261-7.
218. Li N, Beaudart C, Cauley JA, et al. Cost-effectiveness analyses of interventions for osteoporosis in men: a systematic literature review. Pharmacoeconomics. 2023 Apr;41(4):363-391. doi: 10.1007/s40273-022-01239-2.
219. Chai SJ, Yu T, Wang GR, et al. The efficacy and safety of denosumab, risedronate, alendronate, and teriparatide to treat male osteoporosis: a systematic review and Bayesian network meta-analysis. Front Endocrinol (Lausanne). 2025 Jun 19;16:1579101. doi: 10.3389/fendo.2025.1579101.
220. Dong A, Fei X, Huang Y, Huang Y. Efficacy of anti-osteoporosis treatment for men with osteoporosis: a meta-analysis. J Bone Miner Metab. 2023 Mar;41(2):258-267. doi: 10.1007/s00774-023-01407-0.
221. Nayak S, Greenspan SL. Osteoporosis treatment efficacy for men: a systematic review and meta-analysis. J Am Geriatr Soc. 2017 Mar;65(3):490-495. doi: 10.1111/jgs.14668.
222. Lewiecki EM. Operationalizing Treat-to-Target for Osteoporosis. Endocrinol Metab (Seoul). 2021 Apr;36(2):270-278. doi: 10.3803/EnM.2021.970.
223. Foessl I, Dimai HP, Obermayer-Pietsch B. Long-term and sequential treatment for osteoporosis. Nat Rev Endocrinol. 2023 Jul 18. doi: 10.1038/s41574-023-00866-9.
224. Adler RA, El-Hajj Fuleihan G, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016 Jan;31(1):16-35. doi: 10.1002/jbmr.2708.
225. Meier C, Uebelhart B, Aubry-Rozier B, et al. Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the SVGO/ASCO. Swiss Med Wkly. 2017 Aug 16;147:w14484. doi: 10.4414/smw.2017.14484.
226. Tai TW, Chen HY, Shih CA, et al. Asia-Pacific consensus on long-term and sequential therapy for osteoporosis. Osteoporos Sarcopenia. 2024 Mar;10(1):3-10. doi: 10.1016/j.afos.2024.02.001.
227. Dez-Prez A, Gonzlez-Macas J. Inadequate responders to osteoporosis treatment: proposal for an operational definition. Osteoporos Int. 2008 Nov;19(11):1511-6. doi: 10.1007/s00198-008-0659-2.
228. Wu CC, Chen PY, Wang SW, et al. Risk of fracture during androgen deprivation therapy among patients with prostate cancer: a systematic review and meta-analysis of cohort studies. Front. Pharmacol. 2021;12:652979. doi: 10.3389/fphar.2021.652979.
229. Lassemillante AC, Doi SA, Hooper JD, Prins JB, Wright OR. Prevalence of osteoporosis in prostate cancer survivors: a meta-analysis. Endocrine. 2014 Apr;45(3):370-81. doi: 10.1007/s12020-013-0083-z.
230. Lassemillante AC, Doi SA, Hooper JD, Prins JB, Wright OR. Prevalence of osteoporosis in prostate cancer survivors II: a meta-analysis of men not on androgen deprivation therapy. Endocrine. 2015 Nov;50(2):344-54. doi: 10.1007/s12020-015-0536-7.
231. Klotz LH, McNeill IY, Kebabdjian M, Zhang L, Chin JL; Canadian Urology Research Consortium. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the cancer and osteoporosis research with alendronate and leuprolide (CORAL) study. Eur Urol. 2013 May;63(5):927-35. doi: 10.1016/j.eururo.2012.09.007.
232. Choo R, Lukka H, Cheung P, et al. Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy. Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1239-45. doi: 10.1016/j.ijrobp.2012.11.007.
233. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003 Jun;169(6):2008-12. doi: 10.1097/01.ju.0000063820.94994.95.
234. Smith MR, Egerdie B, Hernndez Toriz N, et al. Denosumab HALT Prostate Cancer Study Group. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009 Aug 20;361(8):745-55. doi: 10.1056/NEJMoa0809003.
235. Casado E, Borque-Fernando A, Caamao M, Graa J, Muoz-Rodrguez J, Morote J. Multidisciplinary consensus on the prevention and treatment of osteoporosis and fragility fractures in patients with prostate cancer receiving androgen-deprivation therapy. World J Mens Health. 2022 Jan;40(1):74-86. doi: 10.5534/wjmh.210061.
236. Hannaway N, Prichard R, Leaning D, Sahadevan K, Jiang XY. Guideline on management of bone health in men with prostate cancer. 2022. https://northerncanceralliance.nhs.uk/wp-content/uploads/2022/12/NCA-Guidance-on-BPA-and-Prostate-Cancer-V4_UPLOADED-5-_12_22.pdf.